Bio News
U.S. firm KKR will acquire medical device contract manufacturer Integer for $5.7 billion (approximately 8.1 trillion won). KKR will fund the $5.7 billion purchase through a combination of equity purchase consideration and debt assumption. KKR plans to complete the acquisition within the year of Integer, which reported revenue of $1.85 billion (approximately 2.6 trillion won) last year.
BIOBOOK TEAM
biobookmedia@biobook.co.krRoche’s New Drug for Uveitic Macular Edema Faces FDA Decision in July 2027
BMS Reports Concurrent Phase 3 Success in Idiopathic Pulmonary Fibrosis and Solid Tumors
Merck’s $1.3 trillion eye disease drug raises safety and efficacy concerns: “Limited competitiveness”
CHA Biotech Holds 24.23% Stake in CMG Pharmaceutical as Share Consolidation Reduces Its Share Count
Rural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
MFDS Begins Distribution of Internationally Certified Reference Materials, Including 24 New Items, for a Total of 882
